Clinical trial
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
NCT00272987
Study timeline
Study start (actual)2005-12-13Date precision: day
Registry last updated2023-04-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Neoplasms, Breastunresolved
Interventions
lapatinibDRUG · verified · RxNorm: lapatinib
paclitaxelDRUG · verified · RxNorm: paclitaxel
trastuzumabDRUG · verified · RxNorm: trastuzumab
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
HoustonTexas, United States2ColumbusOhio, United States1DetroitMichigan, United States1CharlestonSouth Carolina, United States1RichmondVirginia, United States1Winston-SalemNorth Carolina, United States1LiègeBelgium1CantonOhio, United States1JacksonMississippi, United States1AmarilloTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00272987 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.